Zacks: Brokerages Anticipate Celldex Therapeutics, Inc. (CLDX) to Post -$0.20 EPS

Wall Street brokerages expect that Celldex Therapeutics, Inc. (NASDAQ:CLDX) will report earnings per share of ($0.20) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Celldex Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.20) and the highest estimate coming in at ($0.19). Celldex Therapeutics posted earnings per share of ($0.30) in the same quarter last year, which suggests a positive year over year growth rate of 33.3%. The firm is scheduled to report its next quarterly earnings report on Tuesday, March 13th.

According to Zacks, analysts expect that Celldex Therapeutics will report full year earnings of ($0.93) per share for the current year, with EPS estimates ranging from ($1.07) to ($0.86). For the next year, analysts expect that the business will report earnings of ($0.90) per share, with EPS estimates ranging from ($1.09) to ($0.59). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Celldex Therapeutics.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.07. The business had revenue of $3.90 million for the quarter, compared to analyst estimates of $1.30 million. Celldex Therapeutics had a negative net margin of 1,088.58% and a negative return on equity of 46.94%. The company’s revenue for the quarter was up 77.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.29) earnings per share.

CLDX has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, November 7th. ValuEngine lowered shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Cantor Fitzgerald reiterated a “buy” rating and issued a $9.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday, September 26th. Finally, WBB Securities reiterated a “buy” rating and issued a $10.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, December 6th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $7.05.

Shares of Celldex Therapeutics (CLDX) traded down $0.03 on Thursday, hitting $2.94. 863,091 shares of the stock were exchanged, compared to its average volume of 1,659,007. Celldex Therapeutics has a twelve month low of $2.20 and a twelve month high of $4.07.

Large investors have recently bought and sold shares of the stock. TSP Capital Management Group LLC grew its position in Celldex Therapeutics by 6.8% in the 2nd quarter. TSP Capital Management Group LLC now owns 1,135,748 shares of the biopharmaceutical company’s stock valued at $2,805,000 after buying an additional 72,500 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Celldex Therapeutics by 426.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 492,547 shares of the biopharmaceutical company’s stock valued at $1,778,000 after buying an additional 398,978 shares during the last quarter. State of Wisconsin Investment Board grew its position in Celldex Therapeutics by 11.3% in the 2nd quarter. State of Wisconsin Investment Board now owns 835,000 shares of the biopharmaceutical company’s stock valued at $2,062,000 after buying an additional 85,000 shares during the last quarter. Northern Trust Corp grew its position in Celldex Therapeutics by 12.2% in the 2nd quarter. Northern Trust Corp now owns 2,020,797 shares of the biopharmaceutical company’s stock valued at $4,992,000 after buying an additional 219,661 shares during the last quarter. Finally, Virtu KCG Holdings LLC boosted its position in shares of Celldex Therapeutics by 458.6% during the 2nd quarter. Virtu KCG Holdings LLC now owns 117,770 shares of the biopharmaceutical company’s stock worth $291,000 after purchasing an additional 96,687 shares in the last quarter. Hedge funds and other institutional investors own 52.55% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Zacks: Brokerages Anticipate Celldex Therapeutics, Inc. (CLDX) to Post -$0.20 EPS” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2017/12/12/zacks-brokerages-anticipate-celldex-therapeutics-inc-cldx-to-post-0-20-eps.html.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Get a free copy of the Zacks research report on Celldex Therapeutics (CLDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply